高浓度唑来膦酸对人成骨细胞成骨分化及凋亡影响的实验研究

上海口腔医学 ›› 2015, Vol. 24 ›› Issue (5): 389-394.

高浓度唑来膦酸对人成骨细胞成骨分化及凋亡影响的实验研究

胡龙威¹, 韩婧¹, 潘红芽^2*, 徐立群^1*

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科, 上海市口腔医学重点实验室,上海 200011；
2.上海市口腔医学研究所口腔生物工程/再生医学实验室,上海 200011

收稿日期:2015-07-01 修回日期:2015-08-12 出版日期:2015-10-20 发布日期:2015-11-03
通讯作者: 徐立群,E-mail:maxilla@sina.com;潘红芽,E-mail:paulin918@hotmail.com。
作者简介:胡龙威（1991-）,男,硕士研究生,E-mail: handsomelong@163.com

High concentration of zoledronate inhibits osteogenesis differentiation and promotes apoptosis of human osteoblasts

HU Long-wei¹, HAN Jing¹, PAN Hong-ya², XU Li-qun¹

1.Department of Oromaxillofacial Head and Neck Oncology,Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology. Shanghai 200011;
2. Oral Bioengineering Laboratory/Regenerative Medicine

Received:2015-07-01 Revised:2015-08-12 Online:2015-10-20 Published:2015-11-03

摘要/Abstract

摘要： 目的研究高浓度唑来膦酸对体外分离的健康人下颌骨成骨细胞的影响。方法体外分离培养来源于健康人下颌骨的成骨细胞,取P3代成骨细胞,用1 μmol/L、5 μmol/L唑来膦酸分别处理,不加药组为空白对照。以CCK8检测细胞增殖,流式细胞技术检测细胞凋亡,ALP染色及定量分析检测细胞成骨分化,荧光定量PCR检测成骨相关基因ALP、OPN和Runx2的表达,Western免疫印迹检测OPN蛋白的表达。采用SPSS16.0软件包对数据进行统计学分析。结果唑来膦酸处理后的成骨细胞增殖减慢,5 μmol/L处理组较1 μmol/L组增殖更慢。药物处理后的细胞凋亡较对照组增加,且随着药物浓度的增加,凋亡百分比显著上升。1 μmol/L及5 μmol/L唑来膦酸处理后的成骨细胞的成骨分化能力较对照组显著下降。荧光定量PCR结果提示,药物处理后的成骨相关基因ALP、OPN和Runx2的表达显著降低。Western免疫印迹检测结果显示药物处理组OPN蛋白表达量显著下降。结论高浓度唑来膦酸抑制来源于人下颌骨成骨细胞的增殖及成骨分化,促进其凋亡发生。

关键词: 唑来膦酸, 成骨细胞, 颌骨坏死, 凋亡, 成骨分化

Abstract: PURPOSE:To investigate the influence of zoledronate on osteoblasts isolated from human jaw in vitro. METHODS: Osteoblasts were isolated from health human mandible. Third passage of osteoblasts were exposed to zoledronate with different concentrations 0 μmol/L,1 μmol/L,5 μmol/L in vitro. Cell proliferation ability was detected using CCK-8 kit and flow cytometry method was applied to identity cell apoptosis. ALP staining and quantitative analysis were used to evaluate the osteogenesis differentiation of osteoblasts. Real-time PCR were used to measure the gene expression of ALP,OPN and Runx2 and western blotWB was used to detect OPN expression.The difference between each group was analyzed with SPSS 16.0 software package. RESULTS: Cell growth curve indicated that zoledronate treatment groups showed slower growth compared with control group and flow cytometry results indicated higher proportion of apoptosis cells in zoledronate treated groups. ALP staining and quantitative analysis both revealed decreased osteogenesis differentiation ability in zoledronate treated groups. These effect were more obvious in 5 μmol/L treated group than 1μmol/L treated group. Significant down-regulation of of ALP, Runx2 and OPN gene expression were also found in zoledronate treated groups.WB results revealed the decreased expression of OPN in zoledronate treated groups. CONCLUSION: High concentration of zoledronate inhibits osteogenesis differentiation and proliferation ability of human osteoblasts and facilitate their apoptosis.

Key words: Zoledronate, Osteoblast, Osteonecrosis of the jaw, Apoptosis, Osteogenesis differentiation

胡龙威, 韩婧, 潘红芽, 徐立群. 高浓度唑来膦酸对人成骨细胞成骨分化及凋亡影响的实验研究[J]. 上海口腔医学, 2015, 24(5): 389-394.

HU Long-wei, HAN Jing, PAN Hong-ya, XU Li-qun. High concentration of zoledronate inhibits osteogenesis differentiation and promotes apoptosis of human osteoblasts[J]. Shanghai Journal of Stomatology, 2015, 24(5): 389-394.

参考文献

[1] Polascik, TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases [J].Drug Des Devel Ther, 2009,3(1): 27-40.
[2] Ruggiero, SL, Mehrotra B, Rosenberg TJ,et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases [J]. J Oral Maxillofac Surg, 2004,62(5): 527-534.
[3] Ruggiero SL, Dodson TB, Assael LA,et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws [J]. J Oral Maxillofac Surg, 2007,65(3): 369-376.
[4] Ruggiero, SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 13-[5] Pazianas M, Miller P, Blumentals WA,et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics [J]. Clin Ther, 2007, 29(8): 1548-1558.
[6] Agacayak KS, Yuksel H, Atilgan S, et al. Experimental investigation of relationship between trauma and bisphosphonate-related osteonecrosis [J]. Niger J Clin Pract, 2014, 17(5): 559-564.
[7] Polymenidi I, Trombetti A, Carballo S. The risk of bisphosphonate-related osteonecrosis of the jaw [J]. Rev Med Suisse, 2014, 10(446): 1930-1934.
[8] Gartrell BA, Coleman RE, Fizazi K, et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappa B ligand inhibitors in patients with advanced prostate cancer [J]. Eur Urol, 2014, 65(2): 278-286.
[9] Cheong S, Sun S, Kang B, et al. Bisphosphonate uptake in areas of tooth extraction or periapical disease [J]. J Oral Maxillofac Surg, 2014, 72(12): 2461-2468.
[10] Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass [J]. Nature, 2003, 423(6937): 349-355.
[11] 王东胜,鄂刘,吴霞.改良大鼠下颌骨成骨细胞原代培养与鉴定[J]. 中华口腔老年医学杂志,2007,5(4): 226-229.
[12] Rogers MJ, Xiong X, Brown RJ,et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae[J]. Mol Pharmacol,1995,47(2): 398-402.
[13] Russell RG,Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy[J].Osteoporos Int, 2008, 19(6): 733-759.
[14] Statz TA, Guthmiller JM, Humbert LA, et al. Intravenous bisphosphonate-associated osteonecrosis of the jaw [J]. J Periodontol, 2007, 78(11): 2203-2208.
[15] Chim SM, Tickner J, Chow ST,et al. Angiogenic factors in bone local environment [J].Cytokine Growth Factor Rev, 2013, 24(3): 297-310.
[16] Lacey DL, Williams JH, Marshall MJ,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J]. Cell, 1998. 93(2): 165-176.
[17] Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation [J]. Cell, 1997,89(5): 747-754.
[18] Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin [J]. Bone, 2015, [Epub ahead of print].
[19] McKee MD, Pedraza CE, Kaartinen MT. Osteopontin and wound healing in bone [J]. Cells Tissues Organs, 2011. 194(2-4): 313-319.